MarketPulse

beta thalassemia

2 articles
The Motley FoolThe Motley Fool··Adria Cimino

CRISPR Therapeutics Poised for Growth on Casgevy Momentum and Pipeline Expansion

CRISPR Therapeutics eyes growth from Casgevy commercialization and pipeline expansion. FDA-approved gene therapy generates revenue while multiple clinical programs advance toward 2026 milestones.
VRTXCRSPFDA approvalclinical trials
BenzingaBenzinga··Vandana Singh

CRISPR Therapeutics Posts Strong Gene Therapy Gains as Casgevy Adoption Accelerates

CRISPR Therapeutics reports strong Q4 results with Casgevy gene therapy generating $116M revenue and 147 patient initiations, signaling accelerating adoption and market confidence.
LLYVRTXREGNCRSPARWRsickle cell diseaseCasgevy